It belongs to the melanocortin family and binds most strongly to the MC4R receptor, with much weaker activity at MC3R
Non-pharmacological approaches form the foundation of ADHD management and include: Psychoeducation for patients and families about ADHD, its impact, and management strategies Environmental modifications such as structured routines, organisational aids, and minimising distractions Cognitive behavioural therapy (CBT) to address comorbid anxiety, depression, or low self-esteem Parent training programmes for children and adolescents with ADHD Occupational therapy to develop practical coping strategies Pharmacological treatment is recommended when ADHD symptoms cause significant impairment despite environmental modifications
Rush University Otolaryngolgy-Head & Neck Surgery Global Health Symposium, US

Key comparative insights from the benzimidazole class: All benzimidazoles share CYP450-dependent hepatic metabolism, creating a common vulnerability pathway Hepatotoxicity risk across the class is dose-dependent and duration-dependent consistent with the fenbendazole case reports Hepatotoxicity is generally reversible upon discontinuation across all benzimidazoles also consistent with fenbendazole data The mechanism appears to involve both direct metabolite toxicity and immune-mediated components, particularly when combined with immunomodulatory agents Veterinary safety data for fenbendazole shows remarkable tolerability: studies in dogs have documented safety margins of 100 the standard dose without significant hepatotoxicity, suggesting that the human cases represent an uncommon susceptibility pattern rather than inherent high toxicity This class-level perspective reinforces that fenbendazole's hepatotoxic risk is real but predictable, dose-related, and manageable with appropriate monitoring consistent with the safety profile of related compounds that have decades of human clinical use data

At 10 mg, average weight loss jumped to 21.4%, roughly 47 pounds from the same starting weight